Is Monte Rosa Therapeutics, Inc. (GLUE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.1% / 30% | 27.4% / 30% | 0.0% / 30% | 13.97% / 5% | ✗ NOT HALAL |
| DJIM | 3.1% / 33% | 27.4% / 33% | 0.0% / 33% | 13.97% / 5% | ✗ NOT HALAL |
| MSCI | 9.7% / 33% | 84.8% / 33% | 0.0% / 33% | 13.97% / 5% | ✗ NOT HALAL |
| S&P | 3.1% / 33% | 27.4% / 33% | 0.0% / 33% | 13.97% / 5% | ✗ NOT HALAL |
| FTSE | 9.7% / 33% | 84.8% / 33% | 0.0% / 50% | 13.97% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -8.1% | |
| Operating Margin | -1787.7% | |
| Net Margin | -31.2% | |
| Return on Equity (ROE) | -16.9% | |
| Return on Assets (ROA) | -7.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$27M |
| Total Debt | $39M |
| Debt-to-Equity | 16.8 |
| Current Ratio | 6.1 |
| Total Assets | $449M |
Price & Trading
| Last Close | $15.67 |
| 50-Day MA | $18.88 |
| 200-Day MA | $11.99 |
| Avg Volume | 1.6M |
| Beta | 1.6 |
|
52-Week Range
$3.50
| |
About Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Monte Rosa Therapeutics, Inc. (GLUE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Monte Rosa Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Monte Rosa Therapeutics, Inc.'s debt ratio?
Monte Rosa Therapeutics, Inc.'s debt ratio is 3.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.7%.
What are Monte Rosa Therapeutics, Inc.'s key financial metrics?
Monte Rosa Therapeutics, Inc. has a market capitalization of $1.2B, and revenue of $124M. The company maintains a gross margin of -8.1% and a net margin of -31.2%. Return on equity stands at -16.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.